Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 3/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628952 | 0.87 | HSP90AA1 (0.60) | HSP90AA1MAPK14NR3C2PDE9APDE1C | |
| SCHEMBL1630240 | 0.83 | HSP90AA1 (0.72) | HSP90AA1MAPK14NR3C2PDE11AMAPT | |
| SCHEMBL1628956 | 0.81 | HSP90AA1 (0.73) | HSP90AA1MAPK14NR3C2P2RX7 | |
| SCHEMBL1629086 | 0.81 | HSP90AA1 (0.66) | HSP90AA1MAPK14NR3C2MEN1KMT2A | |
| SCHEMBL1630555 | 0.80 | HSP90AA1 (0.74) | HSP90AA1MAPK14NR3C2P2RX7 | |
| SCHEMBL1630516 | 0.79 | HSP90AA1 (0.70) | HSP90AA1NR3C2 | |
| SCHEMBL1629156 | 0.79 | HSP90AA1 (0.67) | HSP90AA1MAPK14NR3C2PDE11AALDH1A1 | |
| SCHEMBL1630432 | 0.79 | HSP90AA1 (0.64) | HSP90AA1MAPK14NR3C2PDE11AMAPT | |
| SCHEMBL1630033 | 0.78 | HSP90AA1 (0.72) | HSP90AA1MAPK14NR3C2PDE11AP2RX7 | |
| SCHEMBL1630551 | 0.78 | HSP90AA1 (0.62) | HSP90AA1MAPK14NR3C2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | claimed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | claimed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | claimed |
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885MAPK14 1929/4885NR3C2 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.